Susquehanna International Group
NKTR icon

Susquehanna International Group’s Nektar Therapeutics NKTR Stock Holding History

Susquehanna International Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2M Buy
433,000
+22,400
+5% +$1.28M ﹤0.01% 1700
2025
Q4 		$17.4M Buy
410,600
+99,600
+32% +$5.57M ﹤0.01% 2360
2025
Q3 		$17.7M Sell
311,000
-139,200
-31% -$4.61M ﹤0.01% 2331
2025
Q2 		$11.6M Buy
450,200
+429,167
+2,040% +$4.82M ﹤0.01% 2641
2025
Q1 		$215K Buy
21,033
+18,473
+722% +$241K ﹤0.01% 10799
2024
Q4 		$35.7K Buy
2,560
+1,240
+94% +$21.9K ﹤0.01% 11798
2024
Q3 		$25.7K Sell
1,320
-740
-36% -$14.1K ﹤0.01% 11571
2024
Q2 		$38.3K Sell
2,060
-6,700
-76% -$141K ﹤0.01% 11509
2024
Q1 		$122K Buy
+8,760
New +$91.7K ﹤0.01% 11084
2023
Q2 		– Sell
-1,107
Closed -$11.6K – 12784
2023
Q1 		$11.6K Buy
+1,107
New +$33.5K ﹤0.01% 12178
2022
Q4 		– Sell
-1,567
Closed -$75K – 13256
2022
Q3 		$75K Sell
1,567
-886
-36% -$52.7K ﹤0.01% 11936
2022
Q2 		$140K Sell
2,453
-16,740
-87% -$1.06M ﹤0.01% 11111
2022
Q1 		$1.55M Buy
19,193
+12,300
+178% +$1.82M ﹤0.01% 6048
2021
Q4 		$1.4M Sell
6,893
-10,047
-59% -$2.18M ﹤0.01% 6395
2021
Q3 		$4.56M Buy
16,940
+11,260
+198% +$2.71M ﹤0.01% 4123
2021
Q2 		$1.46M Buy
5,680
+1,680
+42% +$465K ﹤0.01% 6706
2021
Q1 		$1.2M Buy
4,000
+1,620
+68% +$504K ﹤0.01% 7234
2020
Q4 		$607K Sell
2,380
-4,253
-64% -$1.1M ﹤0.01% 7862
2020
Q3 		$1.65M Buy
6,633
+20
+0.3% +$6.29K ﹤0.01% 4979
2020
Q2 		$2.3M Buy
6,613
+4,573
+224% +$1.43M ﹤0.01% 4241
2020
Q1 		$546K Sell
2,040
-14,827
-88% -$4.59M ﹤0.01% 6744
2019
Q4 		$5.46M Sell
16,867
-2,140
-11% -$621K ﹤0.01% 2861
2019
Q3 		$5.19M Sell
19,007
-1,813
-9% -$665K ﹤0.01% 2671
2019
Q2 		$11.1M Buy
20,820
+4,980
+31% +$2.5M ﹤0.01% 1786
2019
Q1 		$7.98M Sell
15,840
-57,493
-78% -$34.1M ﹤0.01% 1955
2018
Q4 		$36.2M Buy
73,333
+30,333
+71% +$18.3M 0.01% 725
2018
Q3 		$39.3M Sell
43,000
-15,120
-26% -$12.9M 0.01% 832
2018
Q2 		$42.6M Sell
58,120
-18,753
-24% -$21.6M 0.01% 768
2018
Q1 		$123M Buy
76,873
+54,486
+243% +$70.2M 0.04% 338
2017
Q4 		$20.1M Buy
22,387
+11,874
+113% +$7.02M 0.01% 1254
2017
Q3 		$3.79M Sell
10,513
-74
-0.7% -$23.1K ﹤0.01% 2887
2017
Q2 		$3.1M Sell
10,587
-1,533
-13% -$443K ﹤0.01% 3090
2017
Q1 		$4.27M Buy
12,120
+8,340
+221% +$1.87M ﹤0.01% 2529
2016
Q4 		$696K Sell
3,780
-2,240
-37% -$455K ﹤0.01% 6293
2016
Q3 		$1.55M Sell
6,020
-1,200
-17% -$309K ﹤0.01% 3981
2016
Q2 		$1.54M Sell
7,220
-133
-2% -$29.7K ﹤0.01% 4041
2016
Q1 		$1.52M Sell
7,353
-8,207
-53% -$1.58M ﹤0.01% 4277
2015
Q4 		$3.93M Buy
15,560
+3,627
+30% +$746K ﹤0.01% 2865
2015
Q3 		$1.96M Sell
11,933
-3,260
-21% -$577K ﹤0.01% 4324
2015
Q2 		$2.85M Buy
15,193
+5,826
+62% +$1M ﹤0.01% 3954
2015
Q1 		$1.55M Sell
9,367
-1,726
-16% -$355K ﹤0.01% 4840
2014
Q4 		$2.58M Buy
11,093
+2,860
+35% +$611K ﹤0.01% 3986
2014
Q3 		$1.49M Sell
8,233
-15,894
-66% -$3.04M ﹤0.01% 5157
2014
Q2 		$4.64M Buy
24,127
+11,467
+91% +$2.03M ﹤0.01% 3219
2014
Q1 		$2.3M Sell
12,660
-2,100
-14% -$416K ﹤0.01% 4090
2013
Q4 		$2.51M Buy
14,760
+2,160
+17% +$348K ﹤0.01% 3905
2013
Q3 		$1.97M Buy
12,600
+3,940
+45% +$728K ﹤0.01% 4120
2013
Q2 		$1.5M Buy
+8,660
New +$1.33M ﹤0.01% 4363

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Susquehanna International Group's NKTR Position: Q1 2026 in Review

Susquehanna International Group reduced its Nektar Therapeutics (NKTR) stake by 35% in Q1 2026, selling an estimated $7.64M and leaving 249,090 shares worth $17.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2368.

Susquehanna International Group first reported a position in NKTR in Q2 2013 and has held it in 49 quarters since. The position peaked at $64.8M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Susquehanna International Group held 249,090 shares of Nektar Therapeutics worth $17.9M as of Q1 2026.
  • Susquehanna International Group sold 134,220 Nektar Therapeutics shares in Q1 2026, an estimated $7.64M.
  • Nektar Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2368 holding.
  • Susquehanna International Group first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's Nektar Therapeutics position peaked at $64.8M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.